



International Cohort Consortium
of Infectious Diseases

RESPOND Newsletter

September 2026

Dear RESPOND Study Investigators and Collaborators,

The RESPOND Secretariat hopes you have had a wonderful summer. We would like to express our sincere gratitude for your continued work and invaluable contributions to the RESPOND study. Your efforts are greatly appreciated and play an important role in the quality of the research we conduct. Below are the key updates from the RESPOND study since November 2025.

Since its inception, RESPOND has published 33 manuscripts, delivered 45 presentations at international conferences, and influenced guideline changes, including the International AIDS Society (IAS) guidelines. We would like to congratulate all authors and contributors: without the combined efforts of everyone involved in this collaboration, this would not have been possible.

Sincerely,

The RESPOND Secretariat

Study Updates

Dataset 8 (DS8)

Thank you for submitting data for RESPOND Dataset 8. In summary, we now have data on more than 46,000 participants from 19 cohorts. Approximately 29,000 participants currently remain under follow-up from 14 active cohorts.

Dataset 9 (DS9)

Dataset 9 (DS9) opened for data submission on 1st September 2026. The deadline for submission will be **1st December 2026**.

If we have been in contact regarding correction on data errors, please do ensure these are corrected for the new submission.

Deadlines

- Deadline for data submission: **1st December 2026**
- Deadline for resubmission: **14th December 2026**
- Deadline for the Event and CoDe forms submission in REDCap: **1st April 2027** for reimbursement in 2027 and to be included the DS9 analysis.

We kindly remind you that we encourage data managers to submit data as early as possible to allow sufficient time for quality assessment and for cohorts to make any necessary changes before the final resubmission deadline.

Reimbursement

Funding for RESPOND is in place through 2027. We will update you on the negotiations for the continuation beyond 2027.

The budget cuts implemented in September 2025 are continued in dataset 9. As in dataset 8, reimbursement for follow-up forms will be **€15**.

Reimbursement for clinical event forms remains at **€30**.

As announced in 2025, reimbursement for new enrolments has been paused for two datasets and remains paused for dataset 9, except for cohorts where an agreement is in place to reach 1,000 included participants. This will be reassessed in 2027.

We greatly welcome the enrollment of new RESPOND participants who can be contributed *in-kind*. To ensure a smooth process, kindly contact the RESPOND Secretariat (respond.rigshospitalet@regionh.d) before submitting any new participants' data.

We truly appreciate your understanding and continued commitment to RESPOND. Please be assured that RESPOND management remains committed to explore additional funding opportunities to help address these budget constraints.

Collaborating cohorts

To date, we have 14 active cohorts in RESPOND. The collaboration appreciates the ongoing efforts from inactivated cohorts to improve and remains open to reinstating them within the RESPOND consortium once the required standards are met again and funding is in place.

RESPOND Staff update

In January 2026, Julie Laub Erdal joined the RESPOND team in Copenhagen. Julie is a medical doctor; she is doing her PhD in RESPOND and working as a RESPOND project coordinator.

Reminder

If you would like to suggest a new project within RESPOND, please, contact the RESPOND Secretariat (respond.rigshospitalet@regionh.dk) first to discuss the possibilities and practicalities.

Upcoming meetings

Starting in Autumn 2026, the frequency of SSC meetings will be reduced to every 3-4 months, in recognition of the administrative workload and busy schedules of stakeholders. If needed, ad hoc meetings will be scheduled.

- RESPOND Scientific Steering Committee VC, **28th September 2026 at 16:00 CEST**
- Annual RESPOND Scientific Retreat in conjunction with the [HIV Glasgow 2026](#), on Sunday **8th November 2026, 9:00 - 12:00 (UTC/local time), Glasgow, Scotland**
- RESPOND Executive Committee VC in **December 2026 - TBD**

Scientific update

We are now well into Phase Three of RESPOND, with several scientific projects currently ongoing utilising the large study size and geographical heterogeneity addressing questions individual cohorts are unable to. In the coming years, we will continue to focus on clinically pertinent questions related to antiretroviral pharmacovigilance, clinical outcomes, multimorbidity and migrant health in people with HIV.

RESPOND continues to have a strong scientific presence in 2026, with five poster presentations across CROI, IWHOD, AIDS, and the European Society of Cardiology Congress. Key topics include pharmacovigilance studies, including fracture risk and chronic kidney disease, and sex disparities in myocardial infarction among people with HIV. RESPOND will also be present at Glasgow 2026; a total of three abstracts were submitted covering data related to long acting cabotegravir and rilpivirine, use of antiretroviral treatment across age groups and mortality estimations in collaboration with ECDC.

To date, there have been four RESPOND publications in 2026, covering cardiovascular disease incidence with integrase inhibitors, cancer burden among women with HIV, CD4 count trends following common cancers and TB.

For a full overview of all RESPOND presentations and publications, please see the [RESPOND website](#), and to stay up to date with ongoing and upcoming research activities, follow RESPOND on [X](#).

Thank you once again for your ongoing support and contributions to the study. If you have any questions or require further clarification, please don't hesitate to reach out. We look forward to continuing our great collaboration.



Contact

Please always feel free to contact the RESPOND Secretariat at respond.rigshospitalet@regionh.dk.
No question is too small or too big, we are happy to assist in all matters!

RESPOND Secretariat
Rigshospitalet
CHIP, Section 2100

Blegdamsvej 9 · Copenhagen 2100 · Denmark